
Certus250 mg
Beacon Pharmaceuticals PLC
Lapatinib is an oral tyrosine kinase inhibitor used in the treatment of HER2-overexpressing (HER2-positive) breast cancer.
Lapatinib is an oral tyrosine kinase inhibitor used in the treatment of HER2-overexpressing (HER2-positive) breast cancer. HER2 status must be confirmed by an approved test before starting therapy, as efficacy depends on HER2-positive disease.
Lapatinib is not indicated as a single agent (monotherapy) for these indications; it must always be given in combination with capecitabine or letrozole as described above.
| Indication | Lapatinib Dose | Combination Partner Dose |
|---|---|---|
| HER2-positive metastatic breast cancer (with capecitabine) | 1,250 mg (5 x 250 mg tablets) orally once daily, continuously, Days 1-21 of a 21-day cycle | Capecitabine 2,000 mg/m²/day orally in two divided doses, Days 1-14 of a 21-day cycle |
| Hormone receptor-positive, HER2-positive metastatic breast cancer (with letrozole) | 1,500 mg (6 x 250 mg tablets) orally once daily, continuously | Letrozole 2.5 mg orally once daily, continuously |
Administration instructions:
In patients with severe hepatic impairment (Child-Pugh Class C), the dose of Lapatinib should be reduced (e.g., to approximately 750 mg/day for the capecitabine combination and 1,000 mg/day for the letrozole combination), based on pharmacokinetic data showing increased exposure; consult current prescribing information for exact adjustment.
No dose adjustment is required for mild to moderate renal impairment; Lapatinib has not been extensively studied in severe renal impairment, and caution is advised.
Dose interruption, reduction, or permanent discontinuation of Lapatinib may be required for hepatotoxicity, severe diarrhea, QT prolongation, decreased left ventricular ejection fraction, or interstitial lung disease/pneumonitis (see Precautions and Warnings).
The most common adverse effects of Lapatinib, occurring with either combination regimen, include:
Serious but less common effects (see Precautions and Warnings for full detail): hepatotoxicity (including severe, potentially fatal liver injury), QT interval prolongation, interstitial lung disease/pneumonitis, and decreased left ventricular ejection fraction (reduced heart pumping function).
Lapatinib is contraindicated in patients with known severe hypersensitivity (e.g., anaphylaxis) to Lapatinib or to any component of the formulation.
Disclaimer
The information provided is accurate to the best of our knowledge, but it does not replace professional medical advice. We cannot guarantee its completeness or accuracy, and the absence of specific information about a drug should not be taken as an endorsement. We are not responsible for any consequences arising from this information, so please consult a healthcare professional for any concerns or questions.